Bonus BioGroup Management
Management criteria checks 3/4
Bonus BioGroup's CEO is Shai Meretzki, appointed in Apr 2012, has a tenure of 13.08 years. total yearly compensation is ₪2.22M, comprised of 89.2% salary and 10.8% bonuses, including company stock and options. directly owns 32.97% of the company’s shares, worth $24.47M. The average tenure of the management team and the board of directors is 4.5 years and 8.9 years respectively.
Key information
Shai Meretzki
Chief executive officer
₪2.2m
Total compensation
| CEO salary percentage | 89.16% |
| CEO tenure | 13.1yrs |
| CEO ownership | 33.0% |
| Management average tenure | 4.5yrs |
| Board average tenure | 8.9yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | ₪2m | ₪2m | -₪28m |
| Sep 30 2024 | n/a | n/a | -₪29m |
| Jun 30 2024 | n/a | n/a | -₪29m |
| Mar 31 2024 | n/a | n/a | -₪29m |
| Dec 31 2023 | ₪2m | n/a | -₪29m |
| Sep 30 2023 | n/a | n/a | -₪31m |
| Jun 30 2023 | n/a | n/a | -₪40m |
| Mar 31 2023 | n/a | n/a | -₪39m |
| Dec 31 2022 | ₪3m | n/a | -₪39m |
| Sep 30 2022 | n/a | n/a | -₪45m |
| Jun 30 2022 | n/a | n/a | -₪40m |
| Mar 31 2022 | n/a | n/a | -₪52m |
| Dec 31 2021 | ₪11m | n/a | -₪90m |
| Sep 30 2021 | n/a | n/a | -₪82m |
| Jun 30 2021 | n/a | n/a | -₪73m |
| Mar 31 2021 | n/a | n/a | -₪61m |
| Dec 31 2020 | ₪3m | n/a | -₪22m |
| Sep 30 2020 | n/a | n/a | -₪19m |
| Jun 30 2020 | n/a | n/a | -₪21m |
| Mar 31 2020 | n/a | n/a | -₪21m |
| Dec 31 2019 | ₪1m | n/a | -₪22m |
Compensation vs Market: Shai's total compensation ($USD622.94K) is about average for companies of similar size in the US market ($USD655.68K).
Compensation vs Earnings: Shai's compensation has increased whilst the company is unprofitable.
CEO
Shai Meretzki (55 yo)
13.1yrs
Tenure
₪2,215,055
Compensation
Dr. Shai Meretzki, PhD is the Founder of Pluristem Therapeutics, Inc. and Bonus BioGroup Ltd (Formerly BoneUs Therapeutics Ltd). Dr. Meretzki founded the Bonus BioGroup Ltd. He has been the Chief Executive...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 13.1yrs | ₪1.67m | no data | |
| Founder | 13.1yrs | ₪2.22m | 32.97% $ 24.5m | |
| Chief Financial Officer | less than a year | ₪425.55k | no data | |
| Chief Operations Officer | 4.3yrs | ₪694.71k | no data | |
| VP of Innovation & Corporate Development | less than a year | no data | no data | |
| Head of Regulatory Affairs & VP of Clinical Affairs | 4.8yrs | no data | no data |
4.5yrs
Average Tenure
51yo
Average Age
Experienced Management: BBIX.F's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman of the Board | 13.1yrs | ₪1.67m | no data | |
| Founder | 13.1yrs | ₪2.22m | 32.97% $ 24.5m | |
| Member of Business Advisory Board | no data | no data | no data | |
| Non-Executive Director | 13.1yrs | no data | 0.61% $ 451.7k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 4.7yrs | no data | no data | |
| Independent Non-Executive Director | 4.7yrs | no data | no data | |
| Non-Executive Director | 4.7yrs | no data | no data |
8.9yrs
Average Tenure
65yo
Average Age
Experienced Board: BBIX.F's board of directors are considered experienced (8.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 09:00 |
| End of Day Share Price | 2025/03/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bonus BioGroup Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.